Association of polymorphic markers of the lipid metabolism genes with diabetic polyneuropathy in type 1 diabetes mellitus

Molecular Biology

Volumn 39, Issue 2, 2005, Pages 206-209

  Voron'ko, O E ^a   Yakunina, N Yu ^a   Strokov, I A ^b   Lavrova, I N ^c   Nosikov, V V ^a  

^a STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Russian Medical Academy of Postgraduate Education   (Russian Federation)

Author keywords

APOB; APOE; Diabetic polyneuropathy; Human; Polymerase chain reaction; Polymorphic markers; Type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GENE PRODUCT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MUTATIONAL ANALYSIS;

EID: 18844445060     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1007/s11008-005-0030-z     Document Type: Article

References (17)

1. Chowdhury T.A., Dyer P.H., Kumar S., Gibson S.P., Rowe B.R., Davies S.J., Marshall S.M., Morris P.J., Gill G.V., Feeney S., Maxwell P., Savage D., Boulton A.J., Todd J.A., Dunger D., Barnett A.H., Bain S.C. 1998. Association of apolipoprotein ε2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes. 47, 278-280.
2. Araki S., Moczulski D.K., Hanna L., Scott L.J., Warram J.H., Krolewski A.S. 2000. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: Results of case-control and family-based studies. Diabetes. 49, 2190-2195.
3. Araki S.-I., Koya D., Makiishi T., Sugimoto T., Isono M., Kikkawa R., Kashiwagi A., Haneda M. 2003. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes results of a prospective observational follow-up study. Diabetes Care. 26, 2416-2420.
4. Nosikov V.V. 2004. Genomics of diabetes mellitus type 1 and its late complications. Mol. Biol. 38, 150-164.
5. Miettinen T.A. 1991. Impact of ApoE phenotype on the regulation of cholesterol metabolism. Ann. Med. 23, 181-186.
6. Hixson J.E., Vernier D.T. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545-548.
7. Olofsson, S.-O., Bjursell, G., Bostrom, K., Carlsson, P., Elovson, J., Protter, A.A., Reuben, M.A., Bondjers G. 1987. Apolipoprotein B: Structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis. 68, 1-17.
8. Brown M.S., Goldstein J.L. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232, 34-47.
9. Boerwinkle E., Chan L. 1989. A three codon insertion/deletion polymorphism in the signal peptide region of the human apolipoprotein B (APOB) gene directly typed by the polymerase chain reaction. Nucleic Acids Res. 17, 4003.
10. Strokov I.A., Novosadova M.V., Barinov A.N., Yakhno N.N. 2000. Clinical methods for assessing the severity of diabetic polyneuropathy. Nevrol. Zh. 5, 14-18.
11. Dyck P.J., Melton J.L., O'Brien P.C., Service F.G. 1997. Approaches to improve epidemiological studies of diabetic neuropathy: Insights from the Rochester diabetic neuropathy study. Diabetes. 46, 5-8.
12. Johns M.B., Paulus-Thomas J.E. 1989. Purification of human genomic DNA from whole blood using proteinase K treatment followed by phenol-chloroform extraction. Anal. Biochem. 180, 276-278.
13. Budowle B., Baechtel F.S. 1990. Modifications to improve the effectiveness of restriction fragment length polymorphism. Appl. Electrophor. 1, 181-187.
14. Hutchon D.J.R. http: Calculator for confidence intervals for odds ratio: Unmatched case control study.
15. Chiodini B.D., Barlera S., Franzosi M.G., Beceiro V.L., Introna M., Tognoni G. 2003. APOB gene polymorphisms and coronary artery disease: A meta-analysis. Atherosclerosis. 167, 355-366.
16. Zotova E.V., Chistyakov D.A., Savost'yanova K.V., Bursa T.R., Galeev I.V., Strokov V.A., Nosikov V.V. 2003. Association of the SOD2 Ala(-9)Val and SOD3 Arg213Gly polymorphisms with diabetic polyneuropathy in diabetes mellitus type 1. Mol. Biol. 37, 345-348
17. Zotova E.V., Savost'yanov K.V., Chistyakov D.A., Bursa T.R., Galeev I.V., Strokov I.A., Nosikov V.V. 2004. Association of polymorphic markers of the antioxidant enzyme genes with diabetic polyneuropathy in type 1 diabetes mellitus. Mol. Biol. 38, 244-249.